UniQure, Syndax, Erasca Drawing Fresh Analyst Interest
Three clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
Review Worldwide Dividend ETF Performance 5 Year to gauge long-term resilience, consistency, and income potential.
24,171 articlesThree clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
Rental-focused development dominated Q4 2025, with 91,000 rental starts among 96,000 total multifamily starts, a jump...
A lesser-known cloud platform is delivering eye-popping gains as AI demand climbs. Discover why this stock crushing N...
NVIDIA and Alphabet reveal divergent AI strategies, highlighting hardware rails versus cloud-powered services, and si...
A major corporate AI experiment reveals the real obstacles to change are human—habits, time, and permission—posing br...
A deep dive into applied digital's stunning rally, the backlog fueling demand, and the tough questions investors must...
A year of explosive AI-driven demand has propelled Micron to the forefront of memory chips. Now investors wonder if t...
A trading halt and a sharp drop put Lucid in the spotlight, but the company pushed back on bankruptcy chatter. This g...
Four high-profile tech names have shed 23% to 37% in 2026 as the Nasdaq edges higher. Analysts see substantial upside...
In 2025, 50 donors gave a combined $22.4 billion to charity, up 35% from 2024 inflation-adjusted totals. Bill Gates r...
A caller in his 60s with a six-figure income and no retirement savings since 2008 receives a blunt reality check on T...
Markets push higher on resilient earnings and a sturdy job market, with recession risk receding for 2026. Yet traders...